valproic acid has been researched along with Lung Neoplasms in 31 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gastrointestinal and pulmonary carcinoid cells were treated with either VPA or SBHA and lithium chloride for up to 48 hours." | 5.35 | Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. ( Adler, JT; Chen, H; Hottinger, DG; Kunnimalaiyaan, M, 2009) |
| " Patients were treated with escalating doses of decitabine (5-15 mg/m(2)) IV for 10 days in combination with VPA (10-20 mg/kg/day) PO on days 5-21 of a 28-day cycle." | 2.78 | Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. ( Aimiuwu, J; Chan, KK; Chu, BF; Grever, MR; Karpenko, MJ; Liu, Z; Otterson, GA; Villalona-Calero, MA, 2013) |
| "Lung cancer is the most frequent cause of cancer death." | 1.72 | Tumors derived from lung cancer cells respond differently to treatment with sodium valproate (a HDAC inhibitor) in a chicken embryo chorioallantoic membrane model. ( Balnytė, I; Diržiuvienė, R; Lasienė, K; Palubinskienė, J; Šlekienė, L; Stakišaitis, D; Valančiūtė, A, 2022) |
| " In this paper, we have investigated the cytotoxic interaction of ERL and valproic acid (VA) in ERL-resistant NSCLC cells and developed a liquisolid formulation of ERL-VA for improving oral bioavailability of ERL." | 1.51 | Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. ( Bagde, A; Doddapaneni, R; Patel, K; Patki, M; Sekar, V; Singh, M, 2019) |
| "Lung cancer is the most commonly diagnosed cancer worldwide with a high mortality rate." | 1.51 | Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells. ( Akgun, O; Ari, F; Erkisa, M, 2019) |
| "Valproic acid (VPA) has been suggested to be a histone deacetylase inhibitor (HDACI)." | 1.46 | Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1. ( Chen, JH; Ding, ZL; Fu, R; Gu, LZ; Hu, CP; Qin, L; Wan, YF; Wang, Y; Xu, CQ; Zheng, YL, 2017) |
| " Oral dosing of mice results in absorption of intact prodrug with slow systemic hydrolysis yielding higher plasma levels of LY2334737 than gemcitabine and prolonged gemcitabine exposure." | 1.39 | Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts. ( Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER, 2013) |
| "Lung cancer is the leading cause of cancer mortality worldwide and despite efforts made to improve clinical results, continuing poor survival rates indicate that novel therapeutic approaches are needed." | 1.38 | Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. ( Amadori, D; Arienti, C; Brigliadori, G; Carloni, S; Del Soldato, P; Fabbri, F; Pasini, A; Silvestrini, R; Sparatore, A; Tesei, A; Ulivi, P; Zoli, W, 2012) |
| "Valproic acid (VPA), which is an effective antiepileptic drug, is known to inhibit the histone deacetylase activities." | 1.38 | Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells. ( Fujiwara, T; Hashimoto, Y; Kagawa, S; Kawamura, H; Nagai, K; Tanaka, N; Urata, Y; Watanabe, Y, 2012) |
| " The abovementioned activity of VPA as a differentiation agent suggested that it might be worth investigating its possible therapeutic potential in synergistic combination with FTS." | 1.37 | Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. ( Biran, A; Brownstein, M; Haklai, R; Kloog, Y, 2011) |
| "Among the mechanisms of resistance of small cell lung carcinomas (SCLCs) to TRAIL is the lack of caspase-8 expression." | 1.37 | Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. ( Kaminskyy, VO; Surova, OV; Vaculova, A; Zhivotovsky, B, 2011) |
| "Prognosis of small cell lung carcinoma (SCLC) is particularly poor, less than 5% of patients with extensive stage being alive after two years." | 1.36 | Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. ( Albelda, SM; Burny, A; Crisanti, C; Crisanti, MC; Hubaux, R; Kapoor, V; Mascaux, C; Vandermeers, F; Willems, L, 2010) |
| "Gastrointestinal and pulmonary carcinoid cells were treated with either VPA or SBHA and lithium chloride for up to 48 hours." | 1.35 | Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. ( Adler, JT; Chen, H; Hottinger, DG; Kunnimalaiyaan, M, 2009) |
| "Carcinoid tumors are neuroendocrine malignancies that frequently metastasize and secrete hormones that cause debilitating symptoms in patients." | 1.34 | Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. ( Chen, H; Greenblatt, DY; Haymart, M; Jaskula-Sztul, R; Kunnimalaiyaan, M; Ning, L; Vaccaro, AM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 21 (67.74) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Perrino, E | 1 |
| Cappelletti, G | 1 |
| Tazzari, V | 1 |
| Giavini, E | 1 |
| Del Soldato, P | 3 |
| Sparatore, A | 3 |
| Diržiuvienė, R | 1 |
| Šlekienė, L | 1 |
| Palubinskienė, J | 1 |
| Balnytė, I | 1 |
| Lasienė, K | 1 |
| Stakišaitis, D | 1 |
| Valančiūtė, A | 1 |
| Chatziantoniou, A | 1 |
| Zaravinos, A | 1 |
| Guo, W | 1 |
| Chen, Z | 2 |
| Tan, L | 1 |
| Wu, Q | 1 |
| Ren, X | 1 |
| Fu, C | 1 |
| Du, Y | 1 |
| Ren, J | 1 |
| Meng, X | 1 |
| Park, HK | 1 |
| Han, BR | 1 |
| Park, WH | 1 |
| Bensaid, D | 1 |
| Blondy, T | 1 |
| Deshayes, S | 1 |
| Dehame, V | 1 |
| Bertrand, P | 1 |
| Grégoire, M | 1 |
| Errami, M | 1 |
| Blanquart, C | 1 |
| Patel, K | 1 |
| Doddapaneni, R | 1 |
| Patki, M | 1 |
| Sekar, V | 1 |
| Bagde, A | 1 |
| Singh, M | 1 |
| Akgun, O | 1 |
| Erkisa, M | 1 |
| Ari, F | 1 |
| Shirsath, N | 1 |
| Rathos, M | 1 |
| Chaudhari, U | 1 |
| Sivaramakrishnan, H | 1 |
| Joshi, K | 1 |
| Ding, S | 1 |
| Pickard, AJ | 1 |
| Kucera, GL | 1 |
| Bierbach, U | 1 |
| Gavrilov, V | 1 |
| Lavrenkov, K | 1 |
| Ariad, S | 1 |
| Shany, S | 1 |
| Noguchi, S | 1 |
| Eitoku, M | 1 |
| Moriya, S | 1 |
| Kondo, S | 1 |
| Kiyosawa, H | 1 |
| Watanabe, T | 1 |
| Suganuma, N | 1 |
| Ciardiello, C | 1 |
| Roca, MS | 1 |
| Noto, A | 1 |
| Bruzzese, F | 1 |
| Moccia, T | 1 |
| Vitagliano, C | 1 |
| Di Gennaro, E | 1 |
| Ciliberto, G | 1 |
| Roscilli, G | 1 |
| Aurisicchio, L | 1 |
| Marra, E | 1 |
| Mancini, R | 1 |
| Budillon, A | 1 |
| Leone, A | 1 |
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Terao, T | 1 |
| Katayama, Y | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 1 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Zhang, Y | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, X | 1 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Liu, X | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Wang, M | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Chen, JH | 1 |
| Zheng, YL | 1 |
| Xu, CQ | 1 |
| Gu, LZ | 1 |
| Ding, ZL | 1 |
| Qin, L | 1 |
| Wang, Y | 1 |
| Fu, R | 1 |
| Wan, YF | 1 |
| Hu, CP | 1 |
| Platta, CS | 1 |
| Greenblatt, DY | 2 |
| Kunnimalaiyaan, M | 3 |
| Chen, H | 3 |
| Adler, JT | 1 |
| Hottinger, DG | 1 |
| Moody, TW | 1 |
| Switzer, C | 1 |
| Santana-Flores, W | 1 |
| Ridnour, LA | 1 |
| Berna, M | 1 |
| Thill, M | 1 |
| Jensen, RT | 1 |
| Yeh, GC | 1 |
| Roberts, DD | 1 |
| Giaccone, G | 1 |
| Wink, DA | 1 |
| Rui, J | 1 |
| Long, D | 1 |
| Wang, W | 1 |
| Chou, T | 1 |
| Zhang, ZG | 1 |
| Li, XJ | 1 |
| Fang, B | 1 |
| Yuan, W | 1 |
| Luo, Y | 1 |
| Zhou, J | 1 |
| Hubaux, R | 1 |
| Vandermeers, F | 1 |
| Crisanti, MC | 1 |
| Crisanti, C | 1 |
| Kapoor, V | 1 |
| Burny, A | 1 |
| Mascaux, C | 1 |
| Albelda, SM | 1 |
| Willems, L | 2 |
| Biran, A | 1 |
| Brownstein, M | 1 |
| Haklai, R | 1 |
| Kloog, Y | 1 |
| Scherpereel, A | 1 |
| Berghmans, T | 1 |
| Lafitte, JJ | 1 |
| Colinet, B | 1 |
| Richez, M | 1 |
| Bonduelle, Y | 1 |
| Meert, AP | 1 |
| Dhalluin, X | 1 |
| Leclercq, N | 1 |
| Paesmans, M | 1 |
| Sculier, JP | 1 |
| Kaminskyy, VO | 1 |
| Surova, OV | 1 |
| Vaculova, A | 1 |
| Zhivotovsky, B | 1 |
| Tesei, A | 1 |
| Brigliadori, G | 1 |
| Carloni, S | 1 |
| Fabbri, F | 1 |
| Ulivi, P | 1 |
| Arienti, C | 1 |
| Pasini, A | 1 |
| Amadori, D | 1 |
| Silvestrini, R | 1 |
| Zoli, W | 1 |
| Watanabe, Y | 1 |
| Hashimoto, Y | 1 |
| Kagawa, S | 1 |
| Kawamura, H | 1 |
| Nagai, K | 1 |
| Tanaka, N | 1 |
| Urata, Y | 1 |
| Fujiwara, T | 1 |
| Chu, BF | 1 |
| Karpenko, MJ | 1 |
| Liu, Z | 1 |
| Aimiuwu, J | 1 |
| Villalona-Calero, MA | 1 |
| Chan, KK | 1 |
| Grever, MR | 1 |
| Otterson, GA | 1 |
| Pratt, SE | 1 |
| Durland-Busbice, S | 1 |
| Shepard, RL | 1 |
| Donoho, GP | 1 |
| Starling, JJ | 1 |
| Wickremsinhe, ER | 1 |
| Perkins, EJ | 1 |
| Dantzig, AH | 1 |
| Gibbs, JP | 1 |
| Adeyeye, MC | 1 |
| Yang, Z | 1 |
| Shen, DD | 1 |
| Ziauddin, MF | 1 |
| Yeow, WS | 1 |
| Maxhimer, JB | 1 |
| Baras, A | 1 |
| Chua, A | 1 |
| Reddy, RM | 1 |
| Tsai, W | 1 |
| Cole, GW | 1 |
| Schrump, DS | 1 |
| Nguyen, DM | 1 |
| Vaccaro, AM | 1 |
| Jaskula-Sztul, R | 1 |
| Ning, L | 1 |
| Haymart, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma[NCT00634205] | Phase 2 | 45 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for valproic acid and Lung Neoplasms
| Article | Year |
|---|---|
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
2 trials available for valproic acid and Lung Neoplasms
| Article | Year |
|---|---|
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Diseas | 2011 |
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Non-Small-Cell | 2013 |
27 other studies available for valproic acid and Lung Neoplasms
| Article | Year |
|---|---|
New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity.
Topics: Acetylation; Adenocarcinoma; Apoptosis; Blotting, Western; Cell Proliferation; Enzyme Inhibitors; Hi | 2008 |
Tumors derived from lung cancer cells respond differently to treatment with sodium valproate (a HDAC inhibitor) in a chicken embryo chorioallantoic membrane model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chick Embryo; Chickens; Chorioallantoic M | 2022 |
Signatures of Co-Deregulated Genes and Their Transcriptional Regulators in Lung Cancer.
Topics: Adenocarcinoma of Lung; Astemizole; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; | 2022 |
l-Cysteine decorated nanoscale metal-organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cisplatin; Cysteine; Drug Delivery Systems | 2020 |
Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biomarkers; Cell Line, Tumor; Disease M | 2020 |
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Topics: B7-H1 Antigen; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Meth | 2018 |
Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Calcium Compounds; Ca | 2019 |
Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Ce | 2019 |
Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; | 2013 |
Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans | 2014 |
Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cel | 2014 |
Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition.
Topics: Acetylation; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Survival; Collagen Type I; Collagen Typ | 2015 |
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Drug Syne | 2016 |
Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter 1; Carcinoma, Non-Small-Cell Lung | 2017 |
Valproic acid induces Notch1 signaling in small cell lung cancer cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Blotting, We | 2008 |
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoid | 2009 |
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.
Topics: Anethole Trithione; Animals; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proli | 2010 |
[Valproic acid induce the expression of MICA antigen in human lung cancer cells and promote the NK killing effects on the cells].
Topics: Cell Line, Tumor; Cell Proliferation; Histocompatibility Antigens Class I; Humans; Killer Cells, Nat | 2010 |
Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cel | 2010 |
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Blotting, Wes | 2011 |
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.
Topics: Azacitidine; Blotting, Western; Caspase 8; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (C | 2011 |
Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergism; Histone Deacetylase 1; Histone Deacetylase I | 2012 |
Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Topics: Adenoviridae; Adenovirus E1A Proteins; Adenovirus E1B Proteins; Antineoplastic Agents; Cell Line, Tu | 2012 |
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Topics: Administration, Metronomic; Administration, Oral; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line | 2013 |
Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
Topics: Adenocarcinoma; Animals; Biological Transport, Active; Brain; Cattle; Cells, Cultured; Cyclooxygenas | 2004 |
Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor | 2006 |
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoid Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C | 2007 |